Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Stryker received FDA 510(k) clearance for Sonopet 3, the latest version of its ultrasonic bone and soft tissue removal platform. The platform adds enhanced power, precision, and new technologies including RISE and Pulse Control, developed with input from hundreds of surgeons.
Key figures
- Drug Name
- Sonopet 3
- Full launch
- later this fall
- Clearance type
- FDA 510(k)
- First clinical cases
- October 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.